Triple Bless Plus LLC – Trademark Portfolio

Entity Type: 16

Triple Bless Plus LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 25 (Clothing) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include MUSEBEAM, NUTRAPEP, and COMFOMEDIC. The owner is based in Austin, TX.

5900 Balcones Drive, Suite 4000

Austin, TX 78731

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MUSEBEAM
MUSEBEAM
Registered 2023
NUTRAPEP
NUTRAPEP
Registered 2023

Trademark Classifications

Triple Bless Plus LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

25
Clothing (1 filing)

Clothing, footwear, headgear

Frequently Asked Questions

How many trademarks does Triple Bless Plus LLC have?

Triple Bless Plus LLC has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Triple Bless Plus LLC file in?

Triple Bless Plus LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 25 (Clothing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Triple Bless Plus LLC's most well-known trademarks?

Triple Bless Plus LLC's registered trademark portfolio includes well-known marks such as MUSEBEAM, NUTRAPEP, and COMFOMEDIC. These are among 3 currently registered trademarks in the portfolio.

What is Triple Bless Plus LLC's trademark registration success rate?

Triple Bless Plus LLC has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.